Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Injectable Targeted Therapy Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The injectable targeted therapy market has shown substantial growth in recent years. Its valuation is expected to climb from $64.22 billion in 2025 to $71.03 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.6%. This historical expansion can be linked to factors such as a rise in cancer occurrence rates, breakthroughs in monoclonal antibody development, the increasing embrace of biologic therapies, the proliferation of oncology treatment centers, and intensified clinical research activities concerning targeted drugs.
The injectable targeted therapy market is poised for significant expansion in the coming years. This market is projected to reach a valuation of $105.2 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.3%. This anticipated growth during the forecast period is fueled by several factors, including the rising number of approvals for targeted injectable therapies, increased investments in personalized medicine, expanded biologics manufacturing capabilities, a heightened focus on immunotherapy development, and the escalating demand for precision treatment protocols. Key trends characterizing the forecast period encompass the escalating development of precision oncology injectables, the increasing adoption of antibody-based therapeutics, a strengthened focus on targeted drug delivery systems, the broadening of combination injectable therapies, and an intensified emphasis on minimizing off-target toxicity.
Get A Free Sample Report With In-Depth Market Insights:
Injectable Targeted Therapy Market Growth Momentum: What Factors Are Shaping Demand?
The escalating need for personalized medicine is anticipated to drive forward the growth of the injectable targeted therapy market. Personalized medicine represents a healthcare approach that tailors prevention, diagnosis, and treatment based on an individual’s unique genetic, environmental, and lifestyle factors. The rise in personalized medicine is fueled by progress in genomics, which allows for a deeper understanding of individual genetic variations, thereby enabling more precise and targeted treatments that enhance patient outcomes and minimize trial-and-error in therapies. Injectable targeted therapy facilitates personalized medicine by delivering drugs designed to specifically address a patient’s distinct molecular or genetic disease profile, thereby improving efficacy and reducing side effects. For example, in February 2024, the US-based non-profit organization Personalized Medicine Coalition reported that in 2023, the FDA sanctioned 16 new personalized treatments for rare disease patients, which is an increase from six in 2022. The newly approved personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Consequently, the increasing demand for personalized medicine is acting as a catalyst for the expansion of the injectable targeted therapy market.
Injectable Targeted Therapy Market Segment Analysis Spotlighting Growth Areas
The injectable targeted therapy market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Small-Molecules, Immunotoxins, Other Types
2) By Mechanism Of Action: Targeted Inhibition of Signal Transduction Pathways, Targeted Delivery Of Cytotoxic Agents, Immunomodulation
3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular
4) By Application: Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Other Applications
5) By End User: Hospitals, Specialty Clinics, Research Laboratories
Subsegments:
1) By Monoclonal Antibodies: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies
2) By Small-Molecules: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mtor Inhibitors
3) By Immunotoxins: Recombinant Immunotoxins, Chemical Conjugates, Fusion Proteins
4) By Other Types: Antibody-Drug Conjugates, Bispecific Antibodies, Peptide-Based Therapeutics
Injectable Targeted Therapy Market Trends Redefining Industry Growth
Leading companies within the injectable targeted therapy market are concentrating on developing novel approaches, such as subcutaneous injections, to enhance drug delivery efficiency, improve patient adherence, and more effectively target specific disease pathways. A subcutaneous injection involves administering medication beneath the skin into the fatty tissue located just under the dermis, allowing for the slow absorption of the drug into the bloodstream. For instance, in August 2025, Eisai Co., Ltd., a Japan-based pharmaceutical company, collaborated with Biogen Inc., a US-based biotechnology company, to obtain FDA approval for LEQEMBI IQLIK, a treatment for early Alzheimer’s disease. This is a convenient, once-weekly subcutaneous injection designed for the maintenance treatment of early Alzheimer’s disease, enabling patients to self-administer it at home following initial intravenous therapy. It contributes to slowing cognitive decline by targeting and clearing amyloid beta plaques and protofibrils, which are key elements driving the progression of Alzheimer’s. This formulation shortens treatment time, reduces systemic side effects compared to IV infusions, and decreases the need for infusion center visits, thereby providing greater independence for patients and their care partners.
Injectable Targeted Therapy Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., Xilio Therapeutics Inc.
View The Full Injectable Targeted Therapy Market Report:
Injectable Targeted Therapy Market Regional Analysis And Leading Geography
North America was the largest region in the injectable targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model